13 results
·
30ms
·
Sources: EU EUDAMED, US FDA
Filters
Regulation: Us FDA
×
SMARTSITE VENTED VIAL ACCESS DEVICE, MODEL TBD
FDA 510(k)
FDA Class 2
·General Hospital
ADD-ON CONDYLE
FDA 510(k)
FDA Class 2
·Dental
CYNOSURE PHOTOGENICA ER
FDA 510(k)
FDA Class 2
·General, Plastic Surgery
COGNIS
FDA Adverse Event
Malfunction
·GUIDANT CRM CLONMEL IRELAND·Product code NIK·April 11, 2013
M SERIES
FDA Adverse Event
Malfunction
·ZOLL MEDICAL CORPORATION·Product code MKJ·March 15, 2011
PROFEMUR MODULAR FEMORAL NECK
FDA Adverse Event
Injury
·WRIGHT MEDICAL TECHNOLOGY, INC.·Product code LWJ·May 20, 2008
MEDTRONIC SURGICAL ANNULOPLASTY PRODUCTS
FDA Adverse Event
Injury
·MEDTRONIC HEART VALVES DIVISION·Product code KRH·October 26, 2021
ACRYLOC GHV 20G
FDA Adverse Event
Malfunction
·DEPUY CMW REG. # 9610921·Product code LOD·May 27, 2014
BIOMET FINNED PRI STEM 40MM
FDA Adverse Event
Injury
·BIOMET ORTHOPEDICS·Product code JWH·July 31, 2017
VANGUARD CR POR FEMORAL-RT 62.5
FDA Adverse Event
Injury
·BIOMET ORTHOPEDICS·Product code JWH·July 31, 2017
E1 VANGUARD CRL TIBIAL BEARING 71/75X12
FDA Adverse Event
Injury
·BIOMET ORTHOPEDICS·Product code JWH·July 31, 2017
Stryker MA204 Bed Model (FL25E) Beds are intended for medical purposes in both general patient care as well as critical care environments. Each uses built-in electric motors and controls which can be operated by the patient, or caregiver, to adjust the height and/or surface contour of the bed.The devices listed above also include movable and latchable side rails which can be lowered or raised to help prevent patient fall and subsequent injury. The Beds include an optional Scale (Models: FL20E, FL25E, FL28C, FL28EX) as well as an optional Bed Exit (1 Zone) or Chaperone
FDA Enforcement
Class II
·Terminated·Stryker Medical Division of Stryker Corporation·July 4, 2012
Boston Scientific COGNIS CRT-D, Cardiac Resynchronization Therapy Defibrillator, models N118, N119. The following models are not available in the US: models N106, N107, P106, P107. Sterilized using ethylene oxide. Product Usage: Boston Scientific cardiac resynchronization therapy defibrillators (CRT-Ds) are indicated for patients with moderate to severe heart failure who remain symptomatic despite stable, optimal heart failure drug therapy and have left ventricular dysfunction and QRS duration > or equal to 120 ms. This family of pulse generators provide a variety of therapies including: -Ventricular tachyarrhythmia therapy, which is used to treat rhythms associated with sudden cardiac death such as VT and VF; -Cardiac Resynchronization Therapy (CRT), which treats heart failure by resynchronizing ventricular contractions through biventricular electrical stimulation; -Bradycardia pacing, including adaptive rate pacing, to detect and treat bradyarrhythmias and to provide cardiac rate support after defibrillation therapy.
FDA Enforcement
Class II
·Terminated·Boston Scientific CRM Corp·October 29, 2014